2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1996

Adenosine A2A Receptor (A2AR) Stimulation Enhances Mitochondrial Metabolism and Mitigates Reactive Oxygen Species-Mediated Mitochondrial Injury
Abstract Number: 2001

Adenosine A2A Receptor Stimulation Regulates Autophagy in Chondrocytes
Abstract Number: 1997

Adenosine A2A Receptors Maintain Chondrocyte and Cartilage Homeostasis By Maintaining Expression of Anti-Inflammatory Regulators (Nur-77) and Suppressing Expression of Pro-Inflammatory Mediators
Abstract Number: 2036

Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2427

Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Abstract Number: 289

Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
Abstract Number: 2319

Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Abstract Number: 55

Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice
Abstract Number: 1618

Adipose Tissue Inflammation in Psoriatic Arthritis: Overexpression of a Wide Array of Inflammatory Mediators and Associations with Disease and Treatment Characteristics
Abstract Number: 475

Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 733

Advanced Chronic Kidney Disease in Lupus Nephritis: Factors Leading to Progression
Abstract Number: 590

Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Abstract Number: 269

Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials
Abstract Number: 2949

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Abstract Number: 1424

After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].